China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a supplementary exclusive distribution and co-promotion agreement with UK pharmaceutical major GlaxoSmithKline (GSK, NYSE: GSK), optimizing and adjusting the original deal concerning the recombinant herpes zoster vaccine. The revised agreement removes the original minimum procurement amount, allowing Zhifei Bio to purchase the contracted products from GSK in stages based on expected market demand, with an anticipated purchase amount of around RMB 21.6 billion during the contract period from 2024 to 2029.
Extended Rights for Zhifei Bio in China
The updated agreement extends the period for which Zhifei Bio holds exclusive import, distribution, and co-promotion rights to the recombinant herpes zoster vaccine in mainland China. The rights are now extended from the end of 2026 to the end of 2034. This extension provides Zhifei Bio with a longer-term commitment to distribute and promote the vaccine in the Chinese market.
Exclusive Cooperation on RSV Vaccine
Furthermore, the deal will see Zhifei Bio and GSK exclusively explore and actively promote the initial 10-year commercial cooperation of a respiratory syncytial virus (RSV) vaccine in mainland China. This collaboration aims to tap into the potential of the RSV vaccine market, offering a new dimension to the partnership between the two companies.-Fineline Info & Tech
